Risks of proton-pump inhibitors: what every doctor should know

Fernández-Fernández, Francisco J; Pía, Gonzalo; Sesma, Pascual

doi:10.5694/j.1326-5377.2009.tb02605.x

Topics

To the Editor: We read with interest Talley’s excellent and informative editorial about the risks associated with proton-pump inhibitors (PPIs).1 Other possible serious side effects of PPIs that need to be taken into account are potential drug interactions with aspirin and clopidogrel.

Internal Medicine, Hospital Arquitecto Marcide, Ferrol, A Coruña, Spain.

Correspondence: fjf-fernandez@terra.es

1. Talley NJ. Risks of proton-pump inhibitors: what every doctor should know [editorial]. Med J Aust 2009; 190: 109-110. <MJA full text>
2. Fernández-Fernández FJ. Might proton pump inhibitors prevent the antiplatelet effects of low- or very low-dose aspirin [letter]? Arch Intern Med 2002; 162: 2248.
3. Kim KA, Park PW, Hong SJ, Park JY. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther 2008; 84: 236-242.
4. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009 Jan 28. [Epub ahead of print].

Online responses are no longer available. Please refer to our instructions for authors page for more information.